Cervomed Inc (CRVO)

Feb 20, 2025

CervoMed (NASDAQ:CRVO) Raised to Buy at D. Boral Capital - Armenian Reporter

Feb 20, 2025

Feb 19, 2025

Why CervoMed (CRVO) Is Advancing Today - Yahoo Canada Finance

Feb 19, 2025

Feb 19, 2025

This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga

Feb 19, 2025

Feb 19, 2025

Boral Capital raises CervoMed stock to Buy, sets $10 target By Investing.com - Investing.com South Africa

Feb 19, 2025

Feb 19, 2025

This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga

Feb 19, 2025

Feb 19, 2025

Boral Capital raises CervoMed stock to Buy, sets $10 target - Investing.com

Feb 19, 2025

Feb 17, 2025

How Are Things Looking For CervoMed Inc (NASDAQ: CRVO) For The Short Term? - Stocks Register

Feb 17, 2025

Feb 13, 2025

CervoMed Inc. (NASDAQ:CRVO) Receives $42.00 Average PT from Brokerages - Defense World

Feb 13, 2025

Feb 04, 2025

Perigon Wealth Management LLC Makes New Investment in CervoMed Inc. (NASDAQ:CRVO) - Defense World

Feb 04, 2025

Feb 01, 2025

CervoMed Provides Update on Neflamapimod DLB Program as - GlobeNewswire

Feb 01, 2025

Jan 31, 2025

CervoMed reports progress in dementia drug trial - MSN

Jan 31, 2025

Jan 31, 2025

CervoMed Updates on Neflamapimod Trials for Dementia - TipRanks

Jan 31, 2025

Jan 31, 2025

CervoMed reports progress in dementia drug trial By Investing.com - Investing.com UK

Jan 31, 2025

Jan 31, 2025

Clinical Trial Setback: CervoMed's Dementia Drug Gets Second Chance with Enhanced Formula - StockTitan

Jan 31, 2025

Jan 29, 2025

CervoMed to Present at the 8th International Lewy Body Dementia Conference - GlobeNewswire

Jan 29, 2025

Jan 29, 2025

Major Breakthrough in Lewy Body Dementia Treatment: CervoMed Reveals Game-Changing Clinical Data - StockTitan

Jan 29, 2025

Jan 24, 2025

CervoMed Inc. (NASDAQ:CRVO) Stock Holdings Lifted by Barclays PLC - Defense World

Jan 24, 2025

Jan 21, 2025

Roth MKM Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN

Jan 21, 2025

Jan 19, 2025

CervoMed Inc. (NASDAQ:CRVO) Receives $42.00 Average Price Target from Analysts - Defense World

Jan 19, 2025

Jan 13, 2025

AWM Investment Company, Inc. Reduces Stake in CervoMed Inc - GuruFocus.com

Jan 13, 2025

Jan 11, 2025

CervoMed (STU:DP8) Momentum Rank : 8 (As of Jan. 11, 2025) - GuruFocus.com

Jan 11, 2025

Jan 09, 2025

Geode Capital Management LLC Raises Holdings in CervoMed Inc. (NASDAQ:CRVO) - Defense World

Jan 09, 2025

Jan 09, 2025

Barclays PLC Acquires 5,919 Shares of CervoMed Inc. (NASDAQ:CRVO) - Defense World

Jan 09, 2025

Jan 04, 2025

Brookline Capital Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN

Jan 04, 2025

Jan 02, 2025

State Street Corp Boosts Stake in CervoMed Inc. (NASDAQ:CRVO) - Defense World

Jan 02, 2025

Dec 25, 2024

Analysts Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $42.00 - Defense World

Dec 25, 2024

Dec 20, 2024

HC Wainwright Brokers Reduce Earnings Estimates for CervoMed - Defense World

Dec 20, 2024

Dec 18, 2024

Enhanced Cognition: Lewy body dementia phase II pumps stock - BioWorld Online

Dec 18, 2024

Dec 17, 2024

HC Wainwright & Co. Downgrades CervoMed (CRVO) - MSN

Dec 17, 2024

Dec 14, 2024

Research Analysts Issue Forecasts for CervoMed Q1 Earnings - Defense World

Dec 14, 2024

Dec 13, 2024

CervoMed (NASDAQ:CRVO) Cut to Hold at Brookline Capital Management - Defense World

Dec 13, 2024

Dec 12, 2024

CervoMed price target lowered to $4 from $45 at Roth MKM - Yahoo Finance

Dec 12, 2024

Dec 12, 2024

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Dec 12, 2024

Dec 12, 2024

CervoMed Awards Key Executive Stock Options in Strategic Talent Acquisition Move - StockTitan

Dec 12, 2024

Dec 12, 2024

CervoMed's dementia drug fails mid-stage trial, shares slump - MSN

Dec 12, 2024

Dec 11, 2024

Chardan Capital Downgrades CervoMed (CRVO) - MSN

Dec 11, 2024

Dec 11, 2024

What Was Behind CervoMed’s Lewy Body Disappointment? - News & Insights

Dec 11, 2024

Dec 11, 2024

CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint - Yahoo Finance

Dec 11, 2024

Dec 11, 2024

Morgan Stanley cuts CervoMed to Underweight on disappointing trial results By Investing.com - Investing.com UK

Dec 11, 2024

Dec 10, 2024

CervoMed stock downgraded to Hold as Phase 2b trial disappoints By Investing.com - Investing.com Canada

Dec 10, 2024

Dec 10, 2024

CervoMed shares rating downgraded after trial data disappoints - Investing.com

Dec 10, 2024

Dec 10, 2024

Jones Trading Downgrades CervoMed (CRVO) - MSN

Dec 10, 2024

Dec 10, 2024

CervoMed's dementia drug fails to meet mid-stage trial goals - MSN

Dec 10, 2024

Dec 10, 2024

CervoMed stock downgraded to Hold as Phase 2b trial disappoints - Investing.com

Dec 10, 2024

Dec 10, 2024

CervoMed shares rating downgraded after trial data disappoints By Investing.com - Investing.com Canada

Dec 10, 2024

Dec 10, 2024

CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease - MSN

Dec 10, 2024

Dec 10, 2024

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets - Yahoo Finance

Dec 10, 2024

Dec 10, 2024

US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift' - Benzinga

Dec 10, 2024

Dec 10, 2024

CervoMed Shares Slide to All-Time Low After Study Failure - MarketWatch

Dec 10, 2024

Dec 10, 2024

CervoMed’s dementia drug fails to meet mid-stage trial goals - 1470 & 100.3 WMBD

Dec 10, 2024

Dec 10, 2024

Late-stage plans on ice as CervoMed's oral drug fails dementia study - FirstWord Pharma

Dec 10, 2024

Dec 10, 2024

CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial - Fierce Biotech

Dec 10, 2024

Dec 10, 2024

CervoMed Inc. Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies - Marketscreener.com

Dec 10, 2024